Breast Cancer | Specialty

Neoadjuvant HER2+ Breast Cancer Options Need Refinement, Expert Says

June 22nd 2016

Lisa A. Carey, MD, comments on the recent I-SPY 2 and KRISTINE findings, the I-SPY 2 program as a whole, and the work ahead in the neoadjuvant landscape of HER2-positive breast cancer.

Breast Cancer Milestones Are Unfolding on Several Fronts

June 20th 2016

During the past 2 years, there have been a number of advancements in the treatment of metastatic breast cancer that include the development of novel agents and new strategies in several disease settings, resulting in improved outcomes for patients.

Biosimilar Era Gets Rolling in Oncology

June 17th 2016

After years of anticipation, biosimilar versions of the most widely administered monoclonal antibodies in oncology care are moving closer to fruition for the US market, starting with a new form of trastuzumab (Herceptin).

Dr. Dickler on MONARCH 1 Results in HR+/HER2- Breast Cancer

June 7th 2016

Maura N. Dickler, MD, Memorial Sloan Kettering Cancer Center, discusses the results of the single-arm MONARCH 1 trial, which examined the efficacy of the CDK4/6 inhibitor abemaciclib in heavily pretreated patients with refractory, hormone-receptor (HR)–positive, HER2-negative advanced breast cancer.

Impressive Upfront Palbociclib PFS Benefit Confirmed in ER+/HER2- Breast Cancer

June 7th 2016

Adding the CDK 4/6 inhibitor palbociclib (Ibrance) to letrozole reduced the risk of disease progression by 42% compared with letrozole alone in patients with ER-positive, HER2-negative advanced or metastatic breast cancer.

Black Women Who Are BRCA Carriers Less Likely to Pursue Breast and Ovarian Cancer Risk Reduction

June 7th 2016

Young black women with breast cancer are much less likely to have BRCA testing or, if they carry a BRCA mutation, to undergo risk-reducing prophylactic mastectomy or salpingo-oophorectomy.

Extending AI Therapy Beyond 5 Years Reduces Recurrence in HR-Positive Breast Cancer

June 6th 2016

Women who extended their adjuvant therapy with an aromatase inhibitor to 10 years after treatment for their early-stage HR-positive breast cancer reduced their risk of recurrence by more than a third and experienced no new toxicities or worsening of quality of life.

Patient-Driven Research Project Aims to Advance Metastatic Breast Cancer Treatment

June 5th 2016

Researchers are hoping that a new nationwide effort to encourage patients to share their tumor samples and clinical information will lead to new discoveries and better treatments.

Abemaciclib Active Against HR+/HER2- Breast Cancer

June 4th 2016

The CDK4/6 inhibitor abemaciclib induced a response rate of nearly 20% in heavily pretreated patients with refractory, HR-positive, HER2-negative advanced breast cancer, according to findings from the phase II MONARCH 1 trial.

Biosimilar Trastuzumab Matches Herceptin in Efficacy and Safety

June 4th 2016

A biosimilar version of trastuzumab demonstrated equivalent efficacy and safety to the FDA-approved branded drug in a randomized phase III study among patients with HER2-positive metastatic breast cancer.

Despite ASCO Mishap, Data Still Intriguing for Sacituzumab Govitecan in TNBC

June 4th 2016

Sacituzumab govitecan (IMMU-132) had an objective response rate of 33% in pretreated patients with triple-negative breast cancer, according to updated findings from a phase II study reported by Immunomedics, the manufacturer of the antibody-drug conjugate.

Communicating Breast Cancer Genetic Testing Results to Patients

May 31st 2016

Cost Considerations in Breast Cancer Genetic Testing

May 31st 2016

Breast Cancer and Genetic Counseling

May 31st 2016

Next-Generation Sequencing in Breast Cancer

May 31st 2016

Clinical Experience with Multi-Gene Panel Use in Breast Cancer

May 31st 2016

Assessing Breast Cancer Risk: Rationale for Multigene Panel Use

May 31st 2016

Understanding the Options in Multi-Gene Panels

May 31st 2016

Breast Cancer Risks: Guidelines for Genetic Testing

May 31st 2016

Mutations and the Risk for Breast Cancer

May 31st 2016